View Author
Shepherd, J.
( J. Shepherd)
patient trial group fluvastatin study angioplasty hospital treatment restenosi follow-up angiographic psc -833 analysis effect angiography trial medication event -833 laboratory myeloid leukemia balloon angioplasty placebo group medication leukemia placebo randomized flare lesion fluvastatin group cr rate balloon lipid result luminal center committee survival table netherland diameter expression agent myeloid cholesterol blood lovastatin death infarction follow-up angiography university evaluation treatment arm induction visit investigator artery serruy resistance 2 treatment arms cancer procedure level prevention disease phase luminal diameter 2 weeks muscle cells chemotherapy multidrug proliferation london change cytogenetic population ratio safety core laboratory month heart
3 Most Recent Publications
|
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
(Article)
Holt, B. van der Verhoef, G.E.G. Knauf, W.U. Dugan, M. Shepherd, J. Piccaluga, P.P. Ossenkoppele, G.J. Vellenga, E. Ferrant, A. Fey, M.F. Crump, M. Theobald, M. Sonneveld, P. Selleslag, D. Löwenberg, B. Burnett, A.K. |
2005-01-01
|
|
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial
(Article)
Shepherd, J. Suryapranata, H. Branzi, A. Serruys, P.W.J.C. Foley, D.P. Pfister, P.J. Feyter, P.J. de Es, G.A. van Melkert, R. Jackson, G. Bonnier, J.J.R.M. Macaya Miguel, C.M. Vrolix, M.C. |
1999-01-01
|
|
Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvavastatin Angioplasty Restenosis (FLARE) Trial
(Article)
Bonnier, J.J.R.M. Jackson, G. Macaya Miguel, C.M. Shepherd, J. Vrolix, M.C. Serruys, P.W.J.C. Foley, D.P. |
1994-01-01
|
